Hyperthermia and associated changes in membrane fluidity potentiate P2X7 activation to promote tumor cell death

DSpace/Manakin Repository

Hyperthermia and associated changes in membrane fluidity potentiate P2X7 activation to promote tumor cell death

Citable link to this page

 

 
Title: Hyperthermia and associated changes in membrane fluidity potentiate P2X7 activation to promote tumor cell death
Author: de Andrade Mello, Paola; Bian, Shu; Savio, Luiz Eduardo Baggio; Zhang, Haohai; Zhang, Jingping; Junger, Wolfgang; Wink, Márcia Rosângela; Lenz, Guido; Buffon, Andréia; Wu, Yan; Robson, Simon Christopher

Note: Order does not necessarily reflect citation order of authors.

Citation: de Andrade Mello, P., S. Bian, L. E. B. Savio, H. Zhang, J. Zhang, W. Junger, M. R. Wink, et al. 2017. “Hyperthermia and associated changes in membrane fluidity potentiate P2X7 activation to promote tumor cell death.” Oncotarget 8 (40): 67254-67268. doi:10.18632/oncotarget.18595. http://dx.doi.org/10.18632/oncotarget.18595.
Full Text & Related Files:
Abstract: Extracellular ATP (eATP) accumulation within the tumor microenvironment (TME) has the potential to activate purinergic signaling. The eATP evoked signaling effects bolster antitumor immune responses while exerting direct cytotoxicity on tumor cells and vascular endothelial cells, mediated at least in part through P2X7 receptors. Approaches to augment purinergic signaling in TME e.g. by ectonucleotidase CD39 blockade, and/or boosting P2X7 functional responses, might be used as immunomodulatory therapies in cancer treatment. In this study, we delineated the translatable strategy of hyperthermia to demonstrate impacts on P2X7 responsiveness to eATP. Hyperthermia (40°C) was noted to enhance eATP-mediated cytotoxicity on MCA38 colon cancer cells. Increased membrane fluidity induced by hyperthermia boosted P2X7 functionality, potentiating pore opening and modulating downstream AKT/PRAS40/mTOR signaling events. When combined with cisplatin or mitomycin C, hyperthermia and eATP together markedly potentiate cancer cell death. Our data indicate that clinically tolerable hyperthermia with modulated P2X7-purinergic signaling will boost efficacy of conventional cancer treatments.
Published Version: doi:10.18632/oncotarget.18595
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620171/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:34492378
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters